Sun Pharma Advanced Research Co. Ltd. (SPARC) Price & Analysis

Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.